Human Adipose-Derived Mesenchymal Stem Cells Modulate Experimental Autoimmune Arthritis by Modifying Early Adaptive T Cell Responses

Stem Cells

Volumn 33, Issue 12, 2015, Pages 3493-3503

  Lopez Santalla, Mercedes ^a   Mancheño Corvo, Pablo ^b   Menta, Ramon ^b   Lopez Belmonte, Juan ^c   Delarosa, Olga ^b   Bueren, Juan A ^a   Dalemans, Wilfried ^d   Lombardo, Eleuterio ^b   Garin, Marina I ^a  

^a CIEMAT   (Spain)

^b TiGenix SAU   (Spain)

^c FARMACROS   (Spain)

^d TiGenix   (Belgium)

Author keywords

Adipose derived mesenchymal stem cells; Arthritis; GM CSF expressing CD4 T cells; Plasticity of Th17 cells; Regulatory T cells

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3;

ADIPOSE DERIVED STEM CELL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; COLLAGEN-INDUCED ARTHRITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE COUNT; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PAW EDEMA; REGULATORY T LYMPHOCYTE; SYNOVITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ADIPOSE TISSUE; ANIMAL; ARTHRITIS, EXPERIMENTAL; DBA MOUSE; IMMUNOLOGY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; XENOGRAFT;

ADIPOSE TISSUE; ANIMALS; ARTHRITIS, EXPERIMENTAL; FEMALE; HETEROGRAFTS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED DBA; TH17 CELLS;

EID: 84983094325     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2113     Document Type: Article

References (65)

1. Salem HK, Thiemermann C,. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells 2010; 28: 585-596.
2. English K, French A, Wood KJ,. Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell 2010; 7: 431-442.
3. Griffin MD, Elliman SJ, Cahill E, et al., Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? Stem Cells 2013; 31: 2033-2041.
4. Chamberlain G, Fox J, Ashton B, et al., Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749.
5. Introna M, Rambaldi A,. Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: Successes and hurdles. Curr Opin Organ Transplant 2015; 20: 72-78.
6. Wang D, Zhang H, Liang J, et al., Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013; 22: 2267-2277.
7. Nagaishi K, Arimura Y, Fujimiya M,. Stem cell therapy for inflammatory bowel disease. J Gastroenterol 2015; 50 (3): 280-286.
8. Duijvestein M, Wildenberg ME, Welling MM, et al., Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29: 1549-1558.
9. Sanchez L, Gutierrez-Aranda I, Ligero G, et al., Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells 2011; 29: 251-262.
10. Martinez-Montiel M, Gomez-Gomez GJ, Flores AI,. Therapy with stem cells in inflammatory bowel disease. World J Gastroenterol 2014; 20: 1211-1227.
11. + T cell subsets and exacerbate experimental autoimmune encephalomyelitis. Stem Cells 2014; 32: 2744-2755.
12. Constantin G, Marconi S, Rossi B, et al., Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27: 2624-2635.
13. Wang L, Wang L, Cong X, et al., Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: Safety and efficacy. Stem Cells Dev 2013; 22: 3192-3202.
14. MacDonald GI, Augello A, De Bari C,. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 2547-2557.
15. Gimble JM, Bunnell BA, Frazier T, et al., Adipose-derived stromal/stem cells: A primer. Organogenesis 2013; 9: 3-10.
16. Janjanin S, Djouad F, Shanti RM, et al., Human palatine tonsil: A new potential tissue source of multipotent mesenchymal progenitor cells. Arthritis Res Ther 2008; 10: R83.
17. Ding DC, Chang YH, Shyu WC, et al., Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy. Cell Transplant 2015; 24: 339-347
18. Chen M, Su W, Lin X, et al., Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. Arthritis Rheum 2013; 65: 1181-1193.
19. Liu J, Yu F, Sun Y, et al., Characteristics and potential applications of human dental tissue-derived mesenchymal stem cells. Stem Cells 2015; 33: 627-638
20. Su WR, Zhang QZ, Shi SH, et al., Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells 2011; 29: 1849-1860.
21. DelaRosa O, Dalemans W, Lombardo E,. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol 2012; 23: 978-983.
22. Kern S, Eichler H, Stoeve J, et al., Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301.
23. Poloni A, Maurizi G, Leoni P, et al., Human dedifferentiated adipocytes show similar properties to bone marrow-derived mesenchymal stem cells. Stem Cells 2012; 30: 965-974.
24. Burmester GR, Feist E, Dorner T,. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10: 77-88.
25. Piper C, Pesenacker AM, Bending D, et al., T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity. Arthritis Rheumatol 2014; 66: 1955-1960.
26. Cook AD, Pobjoy J, Sarros S, et al., Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis 2013; 72: 265-270.
27. Campbell IK, Rich MJ, Bischof RJ, et al., Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998; 161: 3639-3644.
28. Cook AD, Turner AL, Braine EL, et al., Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis. Arthritis Rheum 2011; 63: 2340-2351.
29. Behrens F, Tak PP, Ostergaard M, et al., MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: Results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2015; 74: 1058-1064
30. Greven DE, Cohen ES, Gerlag DM, et al., Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis 2014; 0: 1-7.
31. Burmester GR, Weinblatt ME, McInnes IB, et al., Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1445-1452.
32. Lamacchia C, Palmer G, Seemayer CA, et al., Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum 2010; 62: 452-462.
33. Bettelli E, Korn T, Oukka M, et al., Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051-1057.
34. Califano D, Sweeney KJ, Le H, et al., Diverting T helper cell trafficking through increased plasticity attenuates autoimmune encephalomyelitis. J Clin Invest 2014; 124: 174-187.
35. Lee Y, Awasthi A, Yosef N, et al., Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13: 991-999.
36. Nakayamada S, Takahashi H, Kanno Y, et al., Helper T cell diversity and plasticity. Curr Opin Immunol 2012; 24: 297-302.
37. Codarri L, Gyulveszi G, Tosevski V, et al., RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12: 560-567.
38. Ghoreschi K, Laurence A, Yang XP, et al., Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010; 467: 967-971.
39. + T cells. Science 2010; 327: 1098-1102.
40. + T cell lineage differentiation. Immunity 2009; 30: 646-655.
41. McGeachy MJ, Bak-Jensen KS, Chen Y, et al., TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8: 1390-1397.
42. Park MJ, Park HS, Cho ML, et al., Transforming growth factor beta-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 2011; 63: 1668-1680.
43. Noack M, Miossec P,. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014; 13: 668-677.
44. Obermajer N, Popp FC, Soeder Y, et al., Conversion of Th17 into IL-17A(neg) regulatory T cells: A novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J Immunol 2014; 193: 4988-4999.
45. + T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62-68.
46. Gonzalez MA, Gonzalez-Rey E, Rico L, et al., Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60: 1006-1019.
47. Gonzalez-Rey E, Gonzalez MA, Varela N, et al., Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 241-248.
48. Augello A, Tasso R, Negrini SM, et al., Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56: 1175-1186.
49. Franquesa M, Mensah FK, Huizinga R, et al., Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 2015; 33: 880-891.
50. Soleymaninejadian E, Pramanik K, Samadian E,. Immunomodulatory properties of mesenchymal stem cells: Cytokines and factors. Am J Reprod Immunol 2012; 67: 1-8.
51. Naji A, Rouas-Freiss N, Durrbach A, et al., Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells 2013; 31: 2296-2303.
52. + dendritic cells. Stem Cell Rev 2015; 11: 423-441.
53. Melief SM, Schrama E, Brugman MH, et al., Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013; 31: 1980-1991.
54. Glenn JD, Whartenby KA,. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells 2014; 6: 526-539.
55. Menta R, Mancheno-Corvo P, Del Rio B, et al., Tryptophan concentration is the main mediator of the capacity of adipose mesenchymal stromal cells to inhibit T-lymphocyte proliferation in vitro. Cytotherapy 2014; 16: 1679-1691.
56. Bevaart L, Vervoordeldonk MJ, Tak PP,. Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis? Arthritis Rheum 2010; 62: 2192-2205.
57. McGeachy MJ,. GM-CSF: The secret weapon in the T(H)17 arsenal. Nat Immunol 2011; 12: 521-522.
58. Gagliani N, Magnani CF, Huber S, et al., Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013; 19: 739-746.
59. Cretney E, Kallies A, Nutt SL,. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol 2013; 34: 74-80.
60. Noster R, Riedel R, Mashreghi MF, et al., IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med 2014; 6: 241ra280.
61. Smolen JS, Aletaha D, Redlich K,. The pathogenesis of rheumatoid arthritis: New insights from old clinical data? Nat Rev Rheumatol 2012; 8: 235-243.
62. Gonzalez MA, Gonzalez-Rey E, Rico L, et al., Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136: 978-989.
63. Toupet K, Maumus M, Luz-Crawford P, et al., Survival and biodistribution of xenogenic adipose mesenchymal stem cells is not affected by the degree of inflammation in arthritis. PLoS One 2015; 10: e0114962.
64. Eggenhofer E, Luk F, Dahlke MH, et al., The life and fate of mesenchymal stem cells. Front Immunol 2014; 5.
65. Benaglio F, Vitolo B, Scarabelli M, et al., The draining lymph node in rheumatoid arthritis: Current concepts and research perspectives. Biomed Res Int 2015; 2015: 420251.